NEW YORK, Oct. 9 – Beleaguered functional genomic firm DNA Sciences intends to partner with Bristol-Myers Squibb to investigate genetic variants within an undisclosed drug-discovery gene target, the companies said on Tuesday.

Terms of the deal call for DNA Sciences to use its high-throughput sequencing and genotyping facility to study Bristol-Myers’ gene in normal and affected disease populations.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.